Long-Term Effectiveness and Safety of Infliximab, Golimumab and Golimumab-IV in Rheumatoid Arthritis Patients from a Canadian Prospective Observational Registry

• DOI: 10.21203/rs.2.24628/v2
• Publication Date: 2020-05-14T17:31:56Z
• Authors: Proton Rahman; Philip Baer; Ed Keystone; Denis Choquette; Carter Thorne; Boulos Haraoui; Andrew Chow; Rafat Faraawi; Wojciech Olszynski; John Kelsall; Emmanouil Rampakakis; Allen J. Lehman; Francois Nantel
• Keywords: Golimumab

Abstract Background : Long-term clinical registries are essential tools to evaluate new therapies in a patient population that differs from those randomized trials. The objectives describe the profile of rheumatoid arthritis (RA) patients treated with anti-TNF agents Canadian routine care. Methods RA eligible for treatment Infliximab (IFX), golimumab (GLM) or intravenous (GLM-IV) as per their respective product monographs were enrolled into BioTRAC registry between 2002 and 2017. Study visits occurred at baseline every 6 months thereafter. Effectiveness was assessed by changes disease activity. Safety evaluated incidence adverse events (AEs) drug survival. Results Of 890 IFX-, 530 GLM-SC- 157 GLM-IV-treated patients, proportion females ranged 77.0-86.6%, mean ages 55.8-57.7 duration 6.5-8.6 years. A significant decrease activity parameters (DAS, TJC, SJC, HAQ, AM stiffness, MDGA, PtGA, CRP, ESR) observed over time. Treatment IFX, GLM-SC GLM-IV significantly improved all AEs 105, 113 82.6 /100 PYs SAEs 11.7, 11.2 4.68 respectively. Conclusion Differences characteristics an anti-TNFs time shows evolution modalities All treatments reduced functionality similar fashion. consistent safety profiles IFX GLM. Trial Registration: NCT00741793